These findings demonstrate that SMURF1 may be a potential therapeutic target for pancreatic cancer, providing new perspectives for evaluating the role of SMURF1 inhibitors in the clinical management of human pancreatic cancer. Here, SMURF1 is linked to pancreatic neoplasm.